EP0000677A1 - Parainfluenza virus vaccine and its preparation - Google Patents
Parainfluenza virus vaccine and its preparation Download PDFInfo
- Publication number
- EP0000677A1 EP0000677A1 EP78400058A EP78400058A EP0000677A1 EP 0000677 A1 EP0000677 A1 EP 0000677A1 EP 78400058 A EP78400058 A EP 78400058A EP 78400058 A EP78400058 A EP 78400058A EP 0000677 A1 EP0000677 A1 EP 0000677A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- parainfluenza virus
- passage
- virus
- monkey kidney
- type
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5254—Virus avirulent or attenuated
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18611—Respirovirus, e.g. Bovine, human parainfluenza 1,3
- C12N2760/18634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18711—Rubulavirus, e.g. mumps virus, parainfluenza 2,4
- C12N2760/18734—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Definitions
- the invention is concerned with the adaptation and propagation of parainfluenza types 1, 2 and 3 in tissue cultures prepared from embryonated hens' eggs. More particularly, this invention is directed to the development of live virus vaccines against the parainfluenza group of agents following serial passage in chick embryo tissue culture.
- This procedure involves the steps of A) the isolation of the virulent viruses in any of a variety of cells in culture, and its adaptation to chick embryo tissue culture; B) the development of the attenuated viruses by a plurality of serial passages in chick embryo tissue culture; and C) the preparation of the vaccines from these attenuated live viruses. These steps will be separately explained.
- Isolation and adaptation of parainfluenza virus can be accomplished in chick embryo tissue culture using virus previously propagated in another kind of cell culture, such as monkey kidney or a combination of monkey kidney and embryonated hens' eggs.
- Isolation in the above-mentioned cell cultures can be from clinical material (e.g. throat swab).
- Incubation of infected cultures can be carried out at any temperature between about 30° and about 38°C, preferably at 30-34°C (optimal 32°C) or at 35 to 38°C (optimal 36°C). From about 3 to about 20 serial passages may be employed to attenuate the virus.
- Parainfluenza virus type 1 is isolated and adapted by at least 1 passage in monkey kidney cell culture and at least 1 passage in embryonated hens' eggs. Preferably at least 2 passages in monkey kidney cell culture and at least 2 passages in embryonated hens' eggs are employed.
- Parainfluenza virus types 2 and 3 are isolated and adapted by at least 1 passage in monkey kidney cell culture.
- parainfluenza virus type 2 is isolated and adapted by at least 2 passages in monkey kidney cell culture.
- the virus which has been established in A. to be parainfluenza virus is added to glass bottles containing chick embryo tissue cultures prepared from minced and trypsinized approximately ten-day-old chick embryos.
- the culture medium may be any of those which support cell growth and this may, for example, be the known medium 199 to which calf serum has been added.
- the infected cell cultures are incubated in successive passages at 30-38°C and preferably at 30-34°C (optimal 32°C) and 35-38°C (optimal 36°C). During these passages the virus is replicated in large amount and becomes attenuated.
- the parainfluenza virus harvested after this repeated serial passage is found to be nonpathogenic for monkeys and rodents, to cause little or no clinical reactions in human recipients, and to evoke a satisfactory level of neutralizing antibody.
- the virus infectivity is stabilized by a suitable stabilizer such as sucrose, phosphate, glutamine, human albumin, or mixtures thereof.
- a suitable stabilizer such as sucrose, phosphate, glutamine, human albumin, or mixtures thereof.
- the virus pool is subdivided and filled into appropriate vials for use.
- the product can be stored frozen or preferably dried from the frozen state and kept free of moisture.
- the inoculum is parainfluenza virus type 1 which is obtained as described in A above after 2 passages in grivet monkey kidney cell culture, 8 passages in embryonated hens' eggs, and 9 passages in chick embryo tissue culture.
- the washed tissue is trypsinized at 36°C using 0.25% trypsin (Difco 1:250) in tris saline buffer for approximately two hours.
- the trypsin- cell suspension is harvested through two thicknesses of sterile cheese cloth and centrifuged at 1500 rpm for five minutes.
- Growth medium consists of medium 199 (Morgan, J.F., Morton, H.J., and Parker, R.C., Proc. Soc. Exp. Biol. and Med., 73: 1-8, 1950) containing 2% unheated fetal calf serum and 50 mcg/ml neomycin. Bottle cultures are planted at a concentration of 700,000 viable cells per milliliter. Following incubation at 36°C for 48 to 72 hours, bottle cultures can be used for serial passage or vaccine preparation.
- Chick embryo tissue cultures are prepared in glass bottles using medium 199 containing 2% unheated fetal calf serum as growth medium.
- the growth medium is decanted and the cultures inoculated with 5.0-10.0 ml of undiluted or diluted seed virus per bottle.
- 70 milliliters of medium 199 containing 2% agamma calf serum is added to each bottle, and re-incubated at 30-34°C.
- the bottle cultures are washed four times with Hanks' BSS, 100 milliliters per wash. Following the washing procedure, l00 .
- Appropriate harvest or harvests are selected following completion of infectivity titrations.
- the selected material is removed from the freezer and thawed.
- a sample is removed for control and safety testing.
- the remaining fluid is clarified and a sample removed for monkey safety testing.
- Appropriate additional stabilizer, as mentioned above, is added to the remaining fluid.
- the fluids are distributed into individual vials and lyophilized. Following the lyophilization cycle the vials are capped, sealed and retained for reconstitution as a vaccine by the addition of sterile water (Water for Injection, U.S.P.).
- the potency of the product is based on infectivity titrations in grivet monkey kidney cell cultures.
- Example 1 The procedure of Example 1 is carried out but the incubation of the parainfluenza virus type 1 is in the 35-38°C range and close to 36°C.
- Example 2 The procedure of Example 1 is repeated except substituting parainfluenza virus type 2.
- the inoculum is parainfluenza virus type 2 which is obtained as described in A. above by employing 2 passages in grivet monkey kidney tissue, and 9 passages in chick embryo tissue culture. Similar clinical results are obtained.
- Example 2 The procedure of Example 2 is repeated except employing parainfluenza virus type 2.
- Example 3 The procedure of Example 3 is repeated except substituting parainfluenza virus type 3.
- the inoculum is parainfluenza virus type 3 which is obtained as described in A. above by employing 1 passage in grivet monkey kidney tissue and 9 passages in chick embryo tissue culture. Similar clinical results are obtained.
- Example 2 The procedure of Example 2 is repeated except employing parainfluenza virus type 3.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pulmonology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Description
- In general terms, the invention is concerned with the adaptation and propagation of parainfluenza types 1, 2 and 3 in tissue cultures prepared from embryonated hens' eggs. More particularly, this invention is directed to the development of live virus vaccines against the parainfluenza group of agents following serial passage in chick embryo tissue culture. This procedure involves the steps of A) the isolation of the virulent viruses in any of a variety of cells in culture, and its adaptation to chick embryo tissue culture; B) the development of the attenuated viruses by a plurality of serial passages in chick embryo tissue culture; and C) the preparation of the vaccines from these attenuated live viruses. These steps will be separately explained.
- Isolation and adaptation of parainfluenza virus can be accomplished in chick embryo tissue culture using virus previously propagated in another kind of cell culture, such as monkey kidney or a combination of monkey kidney and embryonated hens' eggs. Isolation in the above-mentioned cell cultures can be from clinical material (e.g. throat swab). Incubation of infected cultures can be carried out at any temperature between about 30° and about 38°C, preferably at 30-34°C (optimal 32°C) or at 35 to 38°C (optimal 36°C). From about 3 to about 20 serial passages may be employed to attenuate the virus. Parainfluenza virus type 1 is isolated and adapted by at least 1 passage in monkey kidney cell culture and at least 1 passage in embryonated hens' eggs. Preferably at least 2 passages in monkey kidney cell culture and at least 2 passages in embryonated hens' eggs are employed. Parainfluenza virus types 2 and 3 are isolated and adapted by at least 1 passage in monkey kidney cell culture. Preferably parainfluenza virus type 2 is isolated and adapted by at least 2 passages in monkey kidney cell culture.
- The virus which has been established in A. to be parainfluenza virus is added to glass bottles containing chick embryo tissue cultures prepared from minced and trypsinized approximately ten-day-old chick embryos. The culture medium may be any of those which support cell growth and this may, for example, be the known medium 199 to which calf serum has been added. After the addition of the virus, the infected cell cultures are incubated in successive passages at 30-38°C and preferably at 30-34°C (optimal 32°C) and 35-38°C (optimal 36°C). During these passages the virus is replicated in large amount and becomes attenuated.
- The above serial passages are performed using undiluted or diluted inoculum and multiple harvests are collected at various intervals. Infectivity titrations are performed in grivet monkey kidney tissue cultures.
- The parainfluenza virus harvested after this repeated serial passage is found to be nonpathogenic for monkeys and rodents, to cause little or no clinical reactions in human recipients, and to evoke a satisfactory level of neutralizing antibody. The virus infectivity is stabilized by a suitable stabilizer such as sucrose, phosphate, glutamine, human albumin, or mixtures thereof. After titration to establish its potency, the virus pool is subdivided and filled into appropriate vials for use. The product can be stored frozen or preferably dried from the frozen state and kept free of moisture.
- The following examples illustrate the present invention without, however, limiting the same thereto.
- The inoculum is parainfluenza virus type 1 which is obtained as described in A above after 2 passages in grivet monkey kidney cell culture, 8 passages in embryonated hens' eggs, and 9 passages in chick embryo tissue culture. Nine to eleven- day-old chick embryos, after removal of the head and extremities, are finely minced under aseptic conditions and the minced tissued washed in several changes of Hank's Balanced Salt Solution (BSS). The washed tissue is trypsinized at 36°C using 0.25% trypsin (Difco 1:250) in tris saline buffer for approximately two hours. The trypsin- cell suspension is harvested through two thicknesses of sterile cheese cloth and centrifuged at 1500 rpm for five minutes. Packed cells are resuspended in growth medium for counting. Growth medium consists of medium 199 (Morgan, J.F., Morton, H.J., and Parker, R.C., Proc. Soc. Exp. Biol. and Med., 73: 1-8, 1950) containing 2% unheated fetal calf serum and 50 mcg/ml neomycin. Bottle cultures are planted at a concentration of 700,000 viable cells per milliliter. Following incubation at 36°C for 48 to 72 hours, bottle cultures can be used for serial passage or vaccine preparation.
- Chick embryo tissue cultures are prepared in glass bottles using medium 199 containing 2% unheated fetal calf serum as growth medium. Three to four days post-planting, the growth medium is decanted and the cultures inoculated with 5.0-10.0 ml of undiluted or diluted seed virus per bottle. Following an adsorption period of one hour at 30-34°C, 70 milliliters of medium 199 containing 2% agamma calf serum is added to each bottle, and re-incubated at 30-34°C. Three to four days post-seeding, the bottle cultures are washed four times with Hanks' BSS, 100 milliliters per wash. Following the washing procedure, l00 . milliliters of medium 199 containing a suitable viral stabilizer is added to each bottle and the cultures in cubated at 30-34°C. Neomycin at a concentration of 50 mcg/ml is incorporated in the growth and maintenance medium. Multiple harvests are collected at 2-4 day intervals and the bottle cultures are refed with fresh maintenance medium containing stabilizer. Infectivity titrations of each harvest are performed in grivet monkey kidney tissue cultures. Each harvest is collected aseptically into a sterile container, samples removed for microbial sterility testing and the remainder is shell-frozen in a dry ice-alcohol bath. The virus-containing fluids are stored at 70°C in an electrically operated freezing unit prior to selection of a harvest or harvests for preparation of the vaccine.
- Appropriate harvest or harvests are selected following completion of infectivity titrations. The selected material is removed from the freezer and thawed. A sample is removed for control and safety testing. The remaining fluid is clarified and a sample removed for monkey safety testing. Appropriate additional stabilizer, as mentioned above, is added to the remaining fluid. The fluids are distributed into individual vials and lyophilized. Following the lyophilization cycle the vials are capped, sealed and retained for reconstitution as a vaccine by the addition of sterile water (Water for Injection, U.S.P.).
- The potency of the product is based on infectivity titrations in grivet monkey kidney cell cultures.
- Tests in man. Clinical studies of parenterally administered parainfluenza virus type 1 (monovalent vaccine) was conducted in children. Good antibody responses were observed with little, if any, untoward clinical-reactions.
- The procedure of Example 1 is carried out but the incubation of the parainfluenza virus type 1 is in the 35-38°C range and close to 36°C.
- The procedure of Example 1 is repeated except substituting parainfluenza virus type 2. The inoculum is parainfluenza virus type 2 which is obtained as described in A. above by employing 2 passages in grivet monkey kidney tissue, and 9 passages in chick embryo tissue culture. Similar clinical results are obtained.
- The procedure of Example 2 is repeated except employing parainfluenza virus type 2.
- The procedure of Example 3 is repeated except substituting parainfluenza virus type 3. The inoculum is parainfluenza virus type 3 which is obtained as described in A. above by employing 1 passage in grivet monkey kidney tissue and 9 passages in chick embryo tissue culture. Similar clinical results are obtained.
- The procedure of Example 2 is repeated except employing parainfluenza virus type 3.
Claims (11)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US81795577A | 1977-07-22 | 1977-07-22 | |
US817955 | 1977-07-22 |
Publications (2)
Publication Number | Publication Date |
---|---|
EP0000677A1 true EP0000677A1 (en) | 1979-02-07 |
EP0000677B1 EP0000677B1 (en) | 1981-08-05 |
Family
ID=25224287
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP78400058A Expired EP0000677B1 (en) | 1977-07-22 | 1978-07-12 | Parainfluenza virus vaccine and its preparation |
Country Status (9)
Country | Link |
---|---|
EP (1) | EP0000677B1 (en) |
JP (1) | JPS5444015A (en) |
DE (1) | DE2860895D1 (en) |
DK (1) | DK326878A (en) |
EG (1) | EG14362A (en) |
ES (1) | ES471766A1 (en) |
IT (1) | IT1105533B (en) |
PT (1) | PT68284A (en) |
ZA (1) | ZA784161B (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0013188A2 (en) * | 1978-12-29 | 1980-07-09 | Merck & Co. Inc. | Parainfluenza virus vaccine and its preparation |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3852918T2 (en) * | 1987-09-28 | 1995-07-13 | Beecham Inc | Pig TGEV virus as a vaccine for dogs. |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS4940926A (en) * | 1972-08-25 | 1974-04-17 |
-
1978
- 1978-07-12 EP EP78400058A patent/EP0000677B1/en not_active Expired
- 1978-07-12 DE DE7878400058T patent/DE2860895D1/en not_active Expired
- 1978-07-12 PT PT68284A patent/PT68284A/en unknown
- 1978-07-13 IT IT50293/78A patent/IT1105533B/en active
- 1978-07-14 ES ES471766A patent/ES471766A1/en not_active Expired
- 1978-07-18 EG EG449/78A patent/EG14362A/en active
- 1978-07-21 DK DK326878A patent/DK326878A/en not_active Application Discontinuation
- 1978-07-21 JP JP8848878A patent/JPS5444015A/en active Pending
- 1978-07-21 ZA ZA784161A patent/ZA784161B/en unknown
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS4940926A (en) * | 1972-08-25 | 1974-04-17 |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0013188A2 (en) * | 1978-12-29 | 1980-07-09 | Merck & Co. Inc. | Parainfluenza virus vaccine and its preparation |
EP0013188A3 (en) * | 1978-12-29 | 1981-01-07 | Merck & Co. Inc. | Parainfluenza virus vaccine and its preparation |
Also Published As
Publication number | Publication date |
---|---|
EP0000677B1 (en) | 1981-08-05 |
ES471766A1 (en) | 1979-10-01 |
JPS5444015A (en) | 1979-04-07 |
IT1105533B (en) | 1985-11-04 |
ZA784161B (en) | 1980-02-27 |
DE2860895D1 (en) | 1981-11-05 |
PT68284A (en) | 1978-08-01 |
DK326878A (en) | 1979-01-23 |
IT7850293A0 (en) | 1978-07-13 |
EG14362A (en) | 1984-03-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US4122167A (en) | Respiratory synctial vaccine | |
Peetermans et al. | Attenuation of rubella virus by serial passage in primary rabbit kidney cell cultures: I. Growth characteristics in vitro and production of experimental vaccines at different passage levels | |
US4224412A (en) | Living virus culture vaccine against canine distemper and method of preparing same | |
CA1109393A (en) | Vaccine and its preparation | |
EP0011864B1 (en) | Attenuated strain of feline infectious peritonitis virus, method for preparing it and vaccine comprising it | |
Patrascu et al. | Vaccination with lyophilized turkey herpesvirus (HVT): minimum infective and protective doses | |
US4324861A (en) | Preparation of live attenuated mumps virus for a vaccine | |
EP0013188B1 (en) | Parainfluenza virus vaccine and its preparation | |
CN104056265B (en) | Porcine circovirus 2 type, Porcine reproductive and respiratory syndrome bigeminy vaccine and preparation method thereof | |
US3555149A (en) | Mumps vaccine and its preparation | |
US4058598A (en) | Cytomegalovirus attenuation method and vaccine | |
US3585266A (en) | Live rabies virus vaccine and method for the production thereof | |
EP0000677B1 (en) | Parainfluenza virus vaccine and its preparation | |
CA1097219A (en) | Respiratory syncytial vaccine | |
US4145252A (en) | Respiratory syncytial vaccine | |
CA2178553A1 (en) | Marek's disease vaccine | |
Williamson et al. | Factors influencing the production of developmental defects in the chick embryo following infection with Newcastle disease virus | |
CA1122898A (en) | Parainfluenza virus vaccine and its preparation | |
US3143474A (en) | Preparation of duck-embryo modified infectious canine hepatitis virus vaccine | |
US3401084A (en) | Rubella vaccine and its preparation | |
US3098011A (en) | Process of producing a vaccine against distemper | |
EP0011865B1 (en) | Feline infectious peritonitis vaccine and process for its preparation | |
US5006335A (en) | Live vaccine against mumps and process for obtaining thereof | |
KR820001230B1 (en) | Process for preparing parainfluenza virus vaccine type2 and type 3 | |
Koprowski et al. | Propagation of Japanese B encephalitis virus in the developing chick embryo |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
AK | Designated contracting states |
Designated state(s): BE CH DE FR GB LU NL SE |
|
17P | Request for examination filed | ||
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
AK | Designated contracting states |
Designated state(s): BE CH DE FR GB LU NL SE |
|
REF | Corresponds to: |
Ref document number: 2860895 Country of ref document: DE Date of ref document: 19811105 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LU Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 19820731 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: SE Payment date: 19830531 Year of fee payment: 6 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: BE Payment date: 19830630 Year of fee payment: 6 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: LU Payment date: 19830706 Year of fee payment: 6 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: CH Payment date: 19840430 Year of fee payment: 7 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: FR Payment date: 19840601 Year of fee payment: 7 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SE Effective date: 19840713 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: BE Effective date: 19840731 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: NL Payment date: 19840731 Year of fee payment: 7 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: DE Payment date: 19840830 Year of fee payment: 7 |
|
BERE | Be: lapsed |
Owner name: MERCK & CO. INC. Effective date: 19840712 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: CH Effective date: 19850731 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: NL Effective date: 19860201 |
|
GBPC | Gb: european patent ceased through non-payment of renewal fee | ||
NLV4 | Nl: lapsed or anulled due to non-payment of the annual fee | ||
REG | Reference to a national code |
Ref country code: CH Ref legal event code: PL |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: FR Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 19860328 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: DE Effective date: 19860402 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: ST |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: GB Effective date: 19881117 |
|
EUG | Se: european patent has lapsed |
Ref document number: 78400058.0 Effective date: 19850612 |
|
PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |